Measuring cognition and function in the preclinical stage of Alzheimer's disease

Sandra Weintraub, Maria C. Carrillo, Sarah Tomaszewski Farias, Terry E. Goldberg, James A. Hendrix*, Judith Jaeger, David S. Knopman, Jessica B. Langbaum, Denise C. Park, Michael T. Ropacki, Sietske A.M. Sikkes, Kathleen A. Welsh-Bohmer, Lisa J. Bain, Robert Brashear, Kumar Budur, Ana Graf, Ferenc Martenyi, Marta Segardahl Storck, Christopher Randolph

*Corresponding author for this work

Research output: Contribution to JournalShort surveyAcademicpeer-review


The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

Original languageEnglish
Pages (from-to)64-75
Number of pages12
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Publication statusPublished - 1 Jan 2018


Dive into the research topics of 'Measuring cognition and function in the preclinical stage of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this